Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lipocine ( (LPCN) ) has shared an announcement.
On January 20, 2026, Lipocine announced it has completed enrollment and dosing of 90 patients in its Phase 3 clinical trial of LPCN 1154, an oral formulation of brexanolone, for the treatment of postpartum depression, with the candidate showing a favorable safety profile to date and no drug-related serious adverse events or treatment discontinuations. The pivotal, randomized, double-blind outpatient study in women with severe postpartum depression is intended to support a planned 505(b)(2) NDA submission in 2026, positioning LPCN 1154 as a potential first-line, at-home, rapid-acting treatment option in an area where current therapies have slow onset and tolerability limitations, and underscoring Lipocine’s strategic focus on high-need neuropsychiatric indications.
The most recent analyst rating on (LPCN) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Overall score is pulled down primarily by weak earnings quality and persistent cash burn despite a debt-free balance sheet. Technicals are strong but extremely overbought, adding near-term risk. Positive Phase 3 trial progress and safety updates provide a meaningful upside catalyst, but valuation remains challenged given ongoing losses.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that leverages a proprietary oral drug delivery technology platform to develop innovative, patient-friendly therapies targeting large markets with significant unmet medical needs. Its pipeline includes candidates for postpartum depression, major depressive disorder, treatment-resistant depression, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, alongside TLANDO, an FDA-approved oral testosterone prodrug for hypogonadism in adult males.
Average Trading Volume: 111,312
Technical Sentiment Signal: Buy
Current Market Cap: $61.79M
See more data about LPCN stock on TipRanks’ Stock Analysis page.